| 25(OH)D |
25-Hydroxyvitamin D |
| ADT |
Androgen deprivation therapy |
| AFF |
Atypical fracture of the femur |
| AI |
Aromatase inhibitor |
| ARR |
Absolute risk reduction |
| BMD |
Bone mineral density |
| BMI |
Body mass index |
| CEE |
Conjugated equine (o)estrogen |
| CI |
Confidence interval |
| DXA |
Dual energy X-ray absorptiometry |
| ER |
(O)Estrogen receptor |
| FLS |
Fracture liaison service |
| FN |
Femoral neck |
| FRAX® |
Fracture Risk Assessment Tool |
| GIT |
Gastrointestinal tract |
| GnRH |
Gonadotropin-releasing hormone |
| GP |
General practitioner |
| HIV |
Human immunodeficiency virus |
| hPTH |
Human parathyroid hormone |
| HR |
Hazard ratio |
| IV |
Intravenous |
| MBS |
Medicare Benefit Schedule |
| MHT |
Menopausal hormone therapy |
| MOF |
Major osteoporotic fracture |
| MRONJ |
Medication-related osteonecrosis of the jaw |
| NHMRC |
National Health and Medical Research Council |
| NNT |
Number needed to treat |
| NSW |
New South Wales |
| OR |
Odds ratio |
| PBS |
Pharmaceutical Benefits Scheme |
| PINP |
Procollagen type 1 amino-terminal propeptide |
| PTH |
Parathyroid hormone |
| QALY |
Quality-adjusted life year |
| QCT |
Quantitative computed tomography |
| RACGP |
The Royal Australian College of General Practitioners |
| RANKL |
Receptor activator of nuclear factor kappa B ligand |
| RaR |
Rate ratio |
| RCT |
Randomised controlled trial |
| RDI |
Recommended dietary intake |
| RR |
Relative risk |
| SD |
Standard deviation |
| SE |
Summary estimate |
| SERMs |
Selective (o)estrogen receptor modulators |
| SFP |
Secondary fracture prevention |
| WHI |
Women’s Health Initiative |
| WHO |
World Health Organization |